| Name | Title | Contact Details |
|---|
Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings.
twoXAR is an artificial intelligence-driven drug discovery company.
Northwest Bioanalytical is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We specialize in recruiting clinical research talent and understand the hiring objectives of our Medical Device, Biotechnology, and Pharmaceutical clients.
Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.